Ardelyx Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Right. Good morning. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having Ardelyx here with us. Welcome. Maybe I'll kick it off with just kind of like a big picture question. Maybe just talk about the progress you guys have made this year on both IBSRELA and XPHOZAH, and just how you're thinking about the outlook.
Sure. First, Dennis, thank you and Jefferies for inviting us. It's great to be here. I think as we exit 2026 and into 2027, it's an incredibly important pivotal transition for the company. I think as you heard this year, and we reinforced in the Q3 earnings, next year is when we're going to pivot into profitability. Certainly for us, as we look at the impact that IBSRELA, which we refer to as the engine of the future of what we're doing at Ardelyx, its continued performance and the benefit it's providing patients is really driving us in what we ultimately aspire to accomplishing. We're right on that cusp of that transition.
I think that time is a critical one for us as we look exiting 2026 with the performance we've seen this year, and the benefit that we're going to see next year as a result of that.
Okay. As it relates to underlying demand for IBSRELA, what are you seeing on the ground? Then we can certainly talk about Sure some of the other access.
I mean, if you take a step back, you look at the number of prescriptions that are written for IBS-C indicated medications, about 7 million-8 million prescriptions. The underlying demand for IBSRELA and the opportunity there is significant, right? We know that 70% or more of patients that are on the current drugs are under-satisfied, not well treated by those medications that are there, leaving only IBSRELA as an option for them. The opportunity is quite significant. As we announced also in Q3, we fully enrolled our chronic idiopathic constipation trial, which is an important indication as it then allows a clinician to not have to differentiate between CIC and IBS-C when prescribing a medication like IBSRELA.
Again, as you look at those top line reading out in the second half of next year, another really important pivotal point for the company as that TAM will then increase by the number of CIC patients that are currently being treated.
Okay. Can you comment on just how material that TAM expansion would be with the CIC data?
Erin, Sue? Yeah, sure. Absolutely.
With CIC, we know that a lot of people, it's about two to three times the size of the current IBS-C market, and we do know that a lot of those patients are treated and successfully treated with over-the-counter. By the time they would then advance into an RX, the chances are it could be around the same size of the market. In terms of the Venn diagram, they're somewhat overlapping. I think for us, the advantage of getting CIC is, you've already got IBS-C and CIC with our two major competitors. I think it's just making it easy for the physician to not have to worry about, does this person have pain or do they not have pain?
Is that dynamic something that you're seeing on the ground today in terms of doctors kind of thinking about IBSRELA as IBS-C and then not necessarily using it, selecting it, because it doesn't have as broad of a label as some of the competitors?
I think right now you have to think about it, right? Is the issue, right? If I come into your office and I have CIC, you're going to either have to fight for an off-label approval and a difficult PA process already, or you're going to have to have me be an ICD-10 code for IBS-C. What it does is actually gets rid of having to think about it, where your patients with CIC or IBS-C would be able to utilize IBSRELA.
Okay. So, talk about the different things that happened this year around IBSRELA guidance. You guys lowered guidance on Q2, then you reiterated on Q3, which is great. Just talk about what some of those dynamics were that you saw in Q2.
Yeah, I mean, so we did take a call down in IBSRELA in Q2. Really, when we started to see some of the payer friction start to happen or really start to come to fruition towards the middle of and the end of Q2, we knew it was prudent that we had to take the guidance down. The initial guidance would have suggested IBSRELA growth this year of like mid-50% range, which in the beginning of the year, we felt like, yes, coming off of a 73% growth, that that was going to be reasonable. So we did take that step down. We now guided to $250 million-$270 million. Really happy to say, we still reiterated that in Q3, and that will be growth in the 30% range. So, we feel very good about that, and that is going to put us on a great trajectory as we move into 2027.
With XPHOZAH, we also reiterated the guidance that we had put out in the beginning of the year, $110 million-$120 million. So again, that is a contributor, and it will remain that way.
Sure. You mentioned friction on the payer level, so maybe give a little bit more color in terms of what you are actually seeing, how that is impacting prescriptions from being filled, and then what you guys are doing about it.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
